BioSpace News Archive

Zymeworks Inc. today announced that management will participate in upcoming investor conferences.

Vistagen today announced that its Chief Executive Officer, Shawn Singh, will participate in a panel discussion regarding emerging therapies for psychiatric disorders and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference.

GC Aesthetics® (GCA®) a privately-held medical technology company providing aesthetic and reconstructive solutions for women’s global healthcare markets is proud to announce the CE approval of the new micro-textured anatomical breast implant LUNA xt™, the first breast implant in the world approved under the new European Medical Device Regulation (MDR).

Tricida, Inc. (Nasdaq: TCDA) announced today that a late-breaking clinical trial abstract on the Phase 3, VALOR-CKD renal outcomes trial has been selected by the American Society of Nephrology (ASN) and the Kidney Week Education Committee for oral presentation in the High-Impact Clinical Trials session at the ASN Kidney Week 2022 meeting that is currently scheduled to take place November 3 to 6, 2022 in Orlando, Florida.

NLS Pharmaceutics Ltd. announces that it has entered into definitive agreements with investors, alongside participation from the Company’s Chairman of the Board of Directors, Ronald Hafner, and George Apostol, the Company’s recently appointed Chief Medical Officer, for the purchase and sale on a private placement basis of 5,194,802 of its common shares.

ARTIDIS AG and The University of Texas MD Anderson Cancer Center announced a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced topline study results showing a survival benefit in the Healey ALS Platform trial of CNM-Au8®, an investigational gold nanocrystal suspension, in participants with amyotrophic lateral sclerosis.

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases, announces that David Vogel has joined the Board of Directors.

Evommune, Inc. announced the appointment of Jeegar Patel, Ph.D., as Chief Scientific Officer.